Ikarian Capital, LLC Merus N.V. Transaction History

Ikarian Capital, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.33 - $27.18 $2.67 Million - $3.96 Million	-145,525 Reduced 69.75%	63,125 $1.66 Million
Q1 2023 May 15, 2023	BUY	$14.25 - $20.5 $750,262 - $1.08 Million	52,650 Added 33.75%	208,650 $3.84 Million
Q4 2022 Feb 14, 2023	BUY	$12.8 - $23.66 $2 Million - $3.69 Million	156,000 New	156,000 $2.41 Million
Q1 2022 May 13, 2022	BUY	$23.58 - $30.91 $65,929 - $86,424	2,796 Added 5.49%	53,703 $1.42 Million
Q3 2021 Nov 15, 2021	SELL	$16.48 - $27.23 $5,207 - $8,604	-316 Reduced 0.62%	50,907 $1.12 Million
Q2 2021 Aug 16, 2021	SELL	$20.0 - $25.48 $1.2 Million - $1.53 Million	-60,000 Reduced 53.95%	51,223 $1.08 Million
Q1 2021 May 17, 2021	SELL	$16.14 - $29.11 $6.87 Million - $12.4 Million	-425,698 Reduced 79.29%	111,223 $2.32 Million
Q4 2020 Feb 12, 2021	BUY	$11.4 - $18.36 $6.12 Million - $9.86 Million	536,921 New	536,921 $9.41 Million

200

61.9M

243K

300K

Ticker MRUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,878,200
Market Cap $2.28B
Description
Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.